The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports emerge of a fifth human case of H5N1 flu linked to ongoing outb
Merck & Co (MSD outside the United States) celebrated the tenth anniversary of the first Keytruda approval at ASCO this year, but the company isn’t resting on its laurels.
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss
The last three slots for projects that will be included in the FDA’s new programme to accelerate the development of therapies for rare diseases have been taken by Moderna,
New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax C
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh